LogicBio Therapeutics

📍 Lexington, United States👥 13 employees
Biotechnology Research🌐 logicbio.com
Website LinkedIn
We are a genome editing company developing genetic medicines for the fight against rare pediatric diseases. GeneRide™ is a promoterless and nuclease-free approach to gene insertion which may improve the safety profile of AAV based gene therapies With GeneRide™, the therapeutic gene is site-specifically integrated into the genome allowing durable gene expression in dividing cells and mature tissues. Furthermore, therapeutic gene expression is regulated by the targeted locus so production can be limited to specific cell types. LogicBio has been acquired by Alexion, AstraZeneca Rare Disease. For future updates on our genome editing program, follow Alexion Pharmaceuticals.
0
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

0 investors
All
Early stage
Mid stage
Late stage
No investors in this category
Frequently asked questions
What industry is LogicBio Therapeutics in?
LogicBio Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is LogicBio Therapeutics based?
LogicBio Therapeutics is headquartered in Lexington, United States.